argenx to Host Conference Call & Webcast to Report Second Quarter 2016 Business Update and Half-Year Financial Results on August 26, 2016

August 03, 2016

Breda, the Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will host a conference call and audio webcast on Friday, August 26, 2016 at 3:00pm CET (9:00am EDT) to discuss financial results for the first half of 2016, as well as to provide a second quarter business update.

To participate in the conference call, please select your phone number below and use the confirmation code 49998398. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here.

A replay of the webcast will also be available at the argenx website.

About argenx

argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.

argenx is listed on the Euronext Brussels exchange under the symbol ARGX.

www.argenx.com

Dial-In Numbers:

Participant Free Call Dial-In Numbers:

UK

0800 694 0257

 

Participant Standard International Dial-In:

UK Standard International

+44 (0) 1452 555 566

 

Participant UK Local Call Dial-In Numbers:

UK

0844 493 3800

UK National Call

0871 700 0345

 

Participant Local Call Dial-In Numbers:

Australia

0290 371 687

Austria

0192 865 68

Belgium

0817 000 61

Croatia

0177 766 11

Czech Republic

2288 804 60

Denmark

3272 7625

Finland

0923 195 187

France

0176 742 428

Germany

0692 222 3479

Germany

0692 222 4918

Hungary

0618 088 303

India

0223 098 5304

Ireland

0143 196 48

Ireland

0150 601 53

Italy

0236 008 146

Latvia

6778 2516

Luxembourg

2088 0695

Netherlands

0207 176 886

New Zealand

0992 917 07

Norway

2156 3013

Poland

2230 701 18

Romania

0318 144 957

Russia

4996 771 036

Slovenia

0160 093 64

South Africa

2110 032 02

Spain

9141 436 69

Sweden

0850 336 434

Switzerland

0565 800 007

USA

1631 510 7498

For further information, please contact:

Joke Comijn, Corporate Communications Manager

+32 (0)477 77 29 44

+32 (0)9 310 34 19

info@argenx.com

 

Beth DelGiacco (US IR)

Stern Investor Relations

+1 212 362 1200

beth@sternir.com

 

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’ actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.